VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

NCRI 2019 | HER-2 conversion: a phenomenon in trastuzumab resistance

Russell Petty
NCRI 2019
Breast Cancer Gastrointestinal Cancer Antibodies Trastuzumab

Russell Petty, BMSC, MB ChB, PhD, MRCP, University of Dundee, Dundee, UK, talks about precision cancer biology and the phenomenon of HER-2 conversion that occurs in trastuzumab resistance. Recorded at the 2019 National Cancer Research Institute (NCRI) Annual Cancer Conference, in Glasgow, UK.
For more information about the NCRI Cancer Conference, visit https://conference.ncri.org.uk.

Genomic biomarkers in metastatic colorectal cancer

More from Russell Petty

3:09
Precision medicine in gastrointestinal cancers: promise and pitfalls
Russell Petty

Related Videos

2:24
Improving fertility and pregnancy issues in young breast cancer patients
Matteo Lambertini
1:58
Targeted therapy in TNBC
Peter Schmid
2:43
Current trials in colorectal cancer investigating panitumumab
Hani Babiker
2:18
The importance of the OlympiA trial for breast cancer patients
Elzbieta Senkus-Konefka
VJOncology VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJOncology is intended for healthcare professionals